26 Oct 2023 , 11:12 AM
Result date: October 27, 2023
Recommendation: Add
Target price: Rs. 1,160
Analysts at IIFL Capital Services expect Cipla’s Revlimid sales to remain flat sequentially at USD 40 million. They believe weak monsoons could have a bearing on the performance of acute players in the September 2023 quarter. Decline in base business products such as Albuterol is another key monitorable.
EBITDA margin could decline 84 basis points over the year-ago quarter and 59 basis points sequentially.
Cipla could post 7% growth in Profit After Tax (PAT) as compared to the year-ago quarter.
| Rs. Million | September 2023 estimates | YoY change | QoQ change |
| Revenue | 64,229 | 10.2% | 1.5% |
| EBITDA | 14,779 | 6.3% | (1.1)% |
| EBITDA margin (%) | 23.0% | (84) bps | (59) bps |
| Profit After Tax | 9,389 | 7.1% | (5.7)% |
Source: IIFL Research
Related Tags
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
